Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06840003 in Malignant Gliomas
NCT02764151Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-06840003 in malignant glioma, sponsored by Pfizer. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 28 days, Number of Participants With Treatment-Emergent Adverse Events at 1 year and 1 more. Started Sep 2016; status: terminated.
02
Drugs
PF-06840003
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT02764151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764151.